Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
NCT07257484 on ClinicalTrials.gov · last registry update 2026-07-22
A small phase 4 — 30 participants, against a typical 75. Due to report 3 December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Percentage of participants completing week 24 visit with all required assessments. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P4
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- Weill Medical College of Cornell University
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2026-06-08
- Primary completion
- 2027-12-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of participants completing week 24 visit with all required assessments
Conditions studied
Obesity (Disorder) · Breast Cancer
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.